Canada Markets closed

Cipher Pharmaceuticals Inc. (CPH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.31000.0000 (0.00%)
At close: 03:59PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • D
    Dennis McCullough
    Filed on SEDI yesterday: 110,545 shares were repurchased and cancelled.
    Cipher bought back a total of 1,541,445 shares over the course of this NCIB which is the maximum allowed.
    Hopefully we get strong quarterly results tomorrow morning.
  • D
    Dennis McCullough
    Just filed on SEDI yesterday: 123,000 shares repurchased and cancelled.
  • D
    Dennis McCullough
    Decent Phase III COMFORT™ study results from Can-Fite (CANF) were released this week. Cipher holds the Canadian distribution rights for CF-101.
  • W
    Wonho
    I just bought few shares today. It’s looking good numbers.
  • G
    Greenberg
    Marekt Cap $35 M / Cash $10 Million/ Shares Out 26 M/ Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year . I think this one is the hottest pick in the canadian healthcare sector my tgt is $10 for next 1-2 years .GL

    ( plecanatide) for the treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation which acquired from Synergy Pharma and MOB-015 for the treatment of Onychomycosis have the biggest potential and both awaiting approval expected in 2H 2019 .

    Cipher Pharma (CPH.TO)

    Market Cap: $35 Million
    Cash: $10 Million

    Price: 1.30
    Shares Out: 26 Million

    Presentaion
    https://filecache.investorroom.com/mr5ircnw_cipher/217/IR%20Deck%20May%202019%20Final.pdf

    Cipher anticipates several key milestones in 2019 that will continue the growth of its Canadian commercial platform, including:

    *Regulatory approval for plecanatide from Health Canada in Q4 2019

    *Regulatory approval for A-101 from Health Canada in Q4 2019

    *Commercial launch of XYDALBA (dalbavancin)

    *North American top line results for MOB-015 in Q4 2019
  • C
    Christine
    Maybe they should look at a dividend
  • D
    Dennis McCullough
    CF101 Phase 3 study topline results were expected in Q1 2022 according to Cipher's most recent MD&A and Can-Fite BioPharma's own website. We should be seeing this news any day now. Over one million Canadians suffer from psoriasis. Strong study results should serve as a catalyst since Cipher holds the Canadian distribution rights for CF101.
  • G
    Greenberg
    APPROVEEEEEEEEEEEED

    Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)..Oct. 18, 2019
    https://finance.yahoo.com/news/cipher-pharmaceuticals-receives-health-canada-110000703.html

    It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months.[B]According to IQVIA the total Canadian laxative and antispasmodic market (prescription and OTC) was valued at over CDN $200 million for the 12 months ending December 2018[/B] .

    Cipher acquired the Canadian rights to develop, market, distribute and sell TRULANCE® from Bausch Health Companies Inc.
  • D
    Dennis McCullough
    A massive buyback of 196,300 shares was just released on SEDI this evening April 11, 2022. This is Cipher's biggest share buyback yet on this latest NCIB which runs from Sept 10, 2021 to Sept 9, 2022 and allows them to buyback & cancel up to 1,541,445 shares (or 10%) of the public float. This brings the total number of shares bought back under the current NCIB to 1,029,600 (or 67% of the total allowed).

    In my opinion, this is the optimum use of the $20.5M cash on the balance sheet while we await results of the second Phase 3 study for MOB-015. Share buybacks are superior to special dividends or a risky product acquisition. I know management is keeping their eyes open for a potential legacy product to buy in an effort to bolster revenue as Absorica declines, but I hope they err on the side of prudence. After all, the first Phase 3 study for MOB-015 already showed safety and efficacy - it just needed reformulation to prevent nail discoloration. The total Rx market for Onychomycosis in Canada is USD $60+ million, and hopefully MOB-015 will be able to take a big chunk of that.
  • D
    Dennis McCullough
    It was just announced yesterday they will potentially be buying back 10% of their public float via another normal course issuer bid. They already have 41% of shares held by insiders. Their last quarter was a blowout. Surprisingly strong revenue numbers from Epuris and Absorica. I think it's safe to say management has turned Cipher around and the trajectory will continue upwards from here. And with a PE of around 9 it continues to be a value entry point.
  • D
    Dennis McCullough
    Good Q1 2022 results just released. EPS of $0.08 was better than I expected! Absorica declined but Epuris revenue picked up the slack.

    An interesting tidbit of information regarding MOB-015 potential:
    "In Canada, according to IQVIA, the total prescription market for Onychomycosis was greater than $75 million CDN at December 31, 2021, with a single product having over 90% market share."

    Moberg estimates the annual global sales potential for MOB-015 to be USD$250-500M.
    Below are estimates for the market size in each region (some estimates are from as late as 2017 and have grown significantly since then):
    Region (Company) $marketUSD
    Canada (Cipher) $57M
    Korea (DongKoo) $40M
    Japan (Taisho) $290M
    Europe (Bayer) $207M
    Scandinavia (Allderma) $10M
    USA (Moberg) $150M-300M
  • D
    Dennis McCullough
    Potential Catalysts:
    -Favorable phase 3 study topline results for CF-101 (for plaque psoriasis)
    -Positive update on the second phase 3 study for MOB-015 (for nail fungus)
    -A product acquisition using some of the $20.5M cash
    -More aggressive monthly share buybacks via the NCIB

    Potential Risks:
    -CF-101 results show inferiority to Otezla®
    -MOB-015 results show visible nail whitening (again)
    -Licensing revenue from Absorica continues to decline
    -The cash stockpile is used in an imprudent manner
  • D
    Dennis McCullough
    The Cipher / Sun Pharma distribution agreement in the United States has been extended through 2026 for the Absorica isotretinoin product.
  • R
    RJ
    I remain optimistic that Cipher has its best days ahead. Decent earnings and potential revenue generators in the pipeline result in my maintaining a position. Like most stocks there is always a speculative component but a stock with good cash reserves, real earnings and potential additional revenue generators with a low PE leads me to believe that our next bit of good news will result in more folks recognizing this stock.
  • D
    Dennis McCullough
    Very impressive FY2021 results just released!
    EPS surged 81% to $0.29 in 2021 (vs $0.16 in 2020)
    Revenue remained steady at $21.9 million (vs $21.6 million)
    Cash stockpile grew to $20.5 million (vs $9.1 million)
    1.2 million shares repurchased and canceled
    Operating expenses continued to decline
    $0 debt on the balance sheet
  • D
    Dennis McCullough
    I read this today on Moberg Pharma's website (Moberg is the same company that makes the popular Kerasal Nail® brand product):
    "the potential revenue for MOB-015 ... is USD 50–100 million each in Japan/Canada"
    https://www.mobergpharma.com/partners/licensing
  • J
    Joe
    Director just loaded up on shares. 13,000
  • D
    D.Jones
    This stock is very underpriced guys! Look at the milestones.. I bought today my last position before it climp at new highs ;)

    Many Insider buying goes on!!

    https://ceo.ca/api/sedi/?symbol=cph&amount=&transaction=&insider=
  • M
    MC
    the kind of stock you buy now and sell too early at 3$ cause it races up to 5$. I had this stock back when it was 5$ and did well with it, it came back under my radar.
  • R
    RJ
    The nail fungus phase 3 looks interesting from a potential addition to the pipeline perspective.